Dendritic Cell Vaccine / University of Miami - LARVOL DELTA

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. (PubMed, JAMA Oncol) - P3 | "To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma...The active treatment was DCVax-L plus SOC temozolomide...In this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone. ClinicalTrials.gov Identifier: NCT00045968."

Clinical • Journal • P3 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial (SNO 2022) - "We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival... Clinically meaningful and statistically significant survival extension was seen in both nGBM and rGBM patients treated with murcidencel and SOC compared with contemporaneous, matched external controls who received SOC alone."

Clinical • P3 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor